BRPI0409459A - novas composições imunogênicas para a prevenção e tratamento de doença meningocócica - Google Patents

novas composições imunogênicas para a prevenção e tratamento de doença meningocócica

Info

Publication number
BRPI0409459A
BRPI0409459A BRPI0409459-0A BRPI0409459A BRPI0409459A BR PI0409459 A BRPI0409459 A BR PI0409459A BR PI0409459 A BRPI0409459 A BR PI0409459A BR PI0409459 A BRPI0409459 A BR PI0409459A
Authority
BR
Brazil
Prior art keywords
immunogenic compositions
prevention
treatment
immunogenic
meningococcal disease
Prior art date
Application number
BRPI0409459-0A
Other languages
English (en)
Inventor
Gary W Zlotnick
Leah D Fletcher
John Farley
Liesel A Bernfield
Robert J Zagursky
Benjamin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0409459A publication Critical patent/BRPI0409459A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"NOVAS COMPOSIçõES IMUNOGêNICAS PARA A PREVENçãO E TRATAMENTO DE DOENçA MENINGOCóCICA". A presente invenção se refere a proteínas de Neisseria ORF2086, proteínas imunogênicas de reação cruzada que podem ser isoladas de cepas nesserial ou preparadas recombinantemente, incluindo porções imunogênicas destas, equivalentes biológicos destas, anticorpos que se ligam imunoespecificamente às precedentes e seqüências de ácido nucléico que codificam cada uma das precedentes, bem como ao uso das mesmas em composições imunogênicas que são efetivas contra infecção por Neisseria meningitidis de grupo de soro B.
BRPI0409459-0A 2003-04-16 2004-04-16 novas composições imunogênicas para a prevenção e tratamento de doença meningocócica BRPI0409459A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46316103P 2003-04-16 2003-04-16
PCT/US2004/011901 WO2004094596A2 (en) 2003-04-16 2004-04-16 Novel immunogenic compositions for the prevention and treatment of meningococcal disease

Publications (1)

Publication Number Publication Date
BRPI0409459A true BRPI0409459A (pt) 2006-05-02

Family

ID=33310752

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409459-0A BRPI0409459A (pt) 2003-04-16 2004-04-16 novas composições imunogênicas para a prevenção e tratamento de doença meningocócica

Country Status (11)

Country Link
US (5) US20070253964A1 (pt)
EP (1) EP1618185A4 (pt)
JP (1) JP2006525330A (pt)
KR (1) KR20060019515A (pt)
CN (1) CN1867354A (pt)
AU (2) AU2004233012A1 (pt)
BR (1) BRPI0409459A (pt)
CA (1) CA2522751A1 (pt)
CO (1) CO5700785A2 (pt)
MX (1) MXPA05011110A (pt)
WO (1) WO2004094596A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
EP1226253A2 (en) 1999-10-29 2002-07-31 Chiron S.P.A. Neisserial antigenic peptides
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
WO2007042326A2 (en) * 2005-10-14 2007-04-19 Intercell Ag Neisseria meningitidis antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
SG174013A1 (en) * 2006-07-27 2011-09-29 Wyeth Corp High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
BR112012010531A2 (pt) * 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
MX340739B (es) * 2010-05-14 2016-07-22 Brookhaven Science Ass Llc Quimeras ospa y su uso en vacunas.
PT3170508T (pt) 2010-06-04 2020-01-16 Wyeth Llc Formulações de vacinas
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) * 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
AU2016221318B2 (en) * 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB202016604D0 (en) * 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
CN113372571A (zh) * 2021-07-05 2021-09-10 云南紫辰集团生物科技有限公司 黄腐酸钾干粉的生产工艺
CN114295845B (zh) * 2021-12-01 2024-07-19 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法降钙素原胶乳比浊检测试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466829A (en) * 1892-01-12 Carpet-stretcher
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
DE19723095C2 (de) * 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
NZ525674A (en) * 1998-02-03 2005-01-28 Ct Disease Contr & Prevention Recombinant lipidated PsaA protein, methods of preparation and use
EP2261347A3 (en) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP4673974B2 (ja) * 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
EP1436385A4 (en) * 2001-09-14 2005-12-14 Invitrogen Corp DNA POLYMERASES AND MUTANTS CORRESPONDING
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Also Published As

Publication number Publication date
AU2004233012A1 (en) 2004-11-04
US20070082006A1 (en) 2007-04-12
AU2010200892A1 (en) 2010-04-01
WO2004094596A8 (en) 2006-06-15
JP2006525330A (ja) 2006-11-09
KR20060019515A (ko) 2006-03-03
WO2004094596A2 (en) 2004-11-04
US20070253964A1 (en) 2007-11-01
US20090202593A1 (en) 2009-08-13
US20070082007A1 (en) 2007-04-12
EP1618185A4 (en) 2009-05-27
EP1618185A2 (en) 2006-01-25
MXPA05011110A (es) 2006-01-24
CA2522751A1 (en) 2004-11-04
CN1867354A (zh) 2006-11-22
CO5700785A2 (es) 2006-11-30
US20070082866A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
JP2024511179A (ja) 百日咳ワクチン
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
BRPI0010612B8 (pt) vacinas
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
HU229968B1 (hu) Sztreptokokkusz oltóanyag
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BRPI0622298A8 (pt) Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
BR112012022688A2 (pt) proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão
BRPI0411875A (pt) método de imunização contra os sorogrupos a e c de neisseria meningitidis
BRPI0508365A (pt) composições imunogênicas para chlamydia pneumoniae
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
BRPI0412419A (pt) proteìna de babésia, ácido nucleico, fragmento de cdna, molécula de dna recombinante, veìculo recombinante vivo, célula hospedeira, vacina, método para a preparação de uma vacina, uso de uma proteìna ou um fragmento imunogênico de referida proteìna, e, testes diagnósticos para a detecção de um ácido nucleico associado com, para a detecção de anticorpos contra, e para a detecção de material antigênico de um organismo da famìlia babesiidae
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
WO2005117956A3 (en) Neisserial vaccines
RU2440369C2 (ru) ГЕНЫ И БЕЛКИ Brachyspira hyodysenteriae И ИХ ПРИМЕНЕНИЕ
BR0313100A (pt) Composição imunogênica, composição imunogênica isolada, vacina, método de tratamento ou prevenção de doença bacteriana gram-negativa, uso da vacina, cepa bacteriana gram-negativa geneticamente manipulada, método para preparar a composição imunogênica, método para preparar a vacina, método de preparar uma imunoglobulina para uso na prevenção ou tratamento de infecção neisserial, preparação de imunoglobulina, preparação farmacêutica, e, uso da preparação farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.